New Drug Shows , Promising Results in Fight Against , Alzheimer's.
BBC reports that a new drug has been hailed as a turning point in the battle against Alzheimer's disease.
.
A global trial confirmed that donanemab, an antibody medicine, can slow cognitive decline.
A global trial confirmed that donanemab, an antibody medicine, can slow cognitive decline.
This is truly a turning point in the fight against Alzheimer's and science is proving that it is possible to slow down the disease, The Alzheimer's Society, via BBC.
BBC reports that the medicine proved effective in the early stages of the disease at clearing protein buildup in the brain.
.
The trials suggest that the medication slowed the pace of the disease by about a third, giving patients more time to retain their mental capacities.
Eli Lilly produces donanemab, which works the same way as competitor Eisai and Biogen's lecanemab, which made global headlines by slowing the disease.
Eli Lilly produces donanemab, which works the same way as competitor Eisai and Biogen's lecanemab, which made global headlines by slowing the disease.
BBC points out that while the results are promising, these medications are not a risk-free form of treatment.
Up to a third of patients reportedly experienced , brain swelling.
.
Two volunteers, and potentially a third, died after developing dangerous swelling in the brain.
Regulators in Europe recently rejected another Alzheimer's drug, aducanumab, citing safety concerns and questions regarding the drug's efficacy
